

HCV TT-034 TRIAL - UPDATE ON PROGRESS

Sydney Australia, 30 October 2014: RNAi therapeutics company, Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) is pleased to provide the following update on the status of the company's first-in-man phase I/II clinical trial of its hepatitis C therapeutic, TT-304.

Trial update

The company has previously reported the appointment of a US-based specialist to manage the TT-034 trial. This appointment is in addition to other activities aimed at increasing the pace of TT-034 clinical trial.

The actions undertaken by the company are bearing fruit.

Significant progress has been made on identifying a second patient for dosing. Three patients are currently progressing through the later stages of screening, and provided one of those patients remains within the clinical parameters required under the protocol, that patient will be dosed following the completion of screening. Currently, dosing is scheduled for early/mid-November.

Progress to bring additional centres online to enhance recruitment is being made, and it is anticipated that Benitec will have two new US based sites commissioned and recruiting patients before calendar year end. The Company is also engaging a patient recruitment firm, and both activities are designed to increase the pool of patients available, and assist in completing the trial in a timely manner.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

Company	Investor relations
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT, OTC: BTEBY) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com